-
Signature
-
/s/ Elizabeth Grammer, Attorney-in-Fact for Michael Raab
-
Issuer symbol
-
ARDX
-
Transactions as of
-
16 Mar 2026
-
Net transactions value
-
-$243,329
-
Form type
-
4
-
Filing time
-
18 Mar 2026, 16:42:26 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| RAAB MICHAEL |
President & CEO, Director |
C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM |
/s/ Elizabeth Grammer, Attorney-in-Fact for Michael Raab |
18 Mar 2026 |
0001321402 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ARDX |
Common Stock |
Options Exercise |
|
+20,833 |
+1.1% |
$0.9900* |
1,856,986 |
16 Mar 2026 |
Direct |
F1 |
| transaction |
ARDX |
Common Stock |
Sale |
$243,329 |
-41,666 |
-2.2% |
$5.84 |
1,816,448 |
16 Mar 2026 |
Direct |
F1, F2, F3 |
| holding |
ARDX |
Common Stock |
|
|
|
|
|
24,364 |
16 Mar 2026 |
Family Trust |
F4 |
| holding |
ARDX |
Common Stock |
|
|
|
|
|
1,000 |
16 Mar 2026 |
Family Trust |
F5 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
ARDX |
Stock Option (Right to Buy) |
Options Exercise |
|
-20,833 |
-5.3% |
$0.000000* |
374,168 |
16 Mar 2026 |
Common Stock |
20,833 |
$0.9900 |
Direct |
F1, F6 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: